Company research
CRYO CELL INTERNATIONAL INC
CIK 862692Updated Sep 26, 2026
SecurityCCEL · NYSE_AMERICAN · equity
Name history
CRYO CELL INTERNATIONAL INC · through Sep 14, 2026
CCEL price & chart
Loading TradingView…
AMEX:CCEL on TradingView ↗About the company
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. The Company, together with its global affiliates, stores more than 250,000 cord blood and cord tissue specimens for the exclusive benefit of newborn babies and their families. In addition to its private bank, Cryo-Cell International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 900 transplants and operates a cord blood donation site at one of the country’s most prominent hospitals, Cedars - Sinai Hospital in Los Angeles, California. Cryo-Cell’s facility is FDA-registered, cGMP-/cGTP-compliant, and licensed in all states requiring licensure. In addition to AABB accreditation as a cord blood facility, Cryo-Cell was the first U.S. private (family-use) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell holds exclusive rights to PrepaCyte-CB, the industry’s most advanced cord blood processing technology. Cryo-Cell’s mission is to provide clients with the premier…
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 61,728,514Source | 64,677,633Source | 61,220,770Source | 64,888,054Source |
| Property, Plant and Equipment, NetUSD | 21,034,372Source | 21,894,263Source | 20,996,883Source | 13,603,115Source |
| GoodwillUSD | 1,941,411Source | 1,941,411Source | 1,941,411Source | 1,941,411Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 863,074Source | 921,254Source | 989,121Source | 1,463,312Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 319,031Source | 560,960Source | 406,067Source | 1,703,958Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 6,846,180Source | 7,309,094Source | 6,576,240Source | 6,043,941Source |
| Inventory, NetUSD | 408,794Source | 657,703Source | 768,877Source | 851,230Source |
| Assets, CurrentUSD | 11,758,221Source | 12,554,593Source | 9,452,837Source | 9,610,185Source |
| Operating Lease, Right-of-Use AssetUSD | 819,626Source | 806,339Source | 1,033,157Source | 606,034Source |
| Other Assets, NoncurrentUSD | 28,935,921Source | 30,228,777Source | 30,771,050Source | 41,674,754Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 80,334,443Source | 77,893,650Source | 72,252,002Source | 66,412,356Source |
| Commitments and ContingenciesUSD | 0Source | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 148,771Source | 148,696Source | 148,492Source | 148,480Source |
| Retained Earnings (Accumulated Deficit)USD | -38,438,238Source | -32,777,626Source | -31,159,182Source | -21,637,513Source |
| Stockholders' Equity Attributable to ParentUSD | -18,605,929Source | -13,216,017Source | -11,031,232Source | -1,524,302Source |
| Additional Paid in Capital, Common StockUSD | 44,708,596Source | 44,268,469Source | 43,411,143Source | 42,597,380Source |
| Liabilities and EquityUSD | 61,728,514Source | 64,677,633Source | 61,220,770Source | 64,888,054Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 19,792,987Source | 21,599,542Source | 20,864,001Source | 19,481,420Source |
| Operating Lease, Liability, CurrentUSD | 430,221Source | 428,334Source | 225,686Source | 297,691Source |
| Accounts Payable, CurrentUSD | 2,870,771Source | 1,882,274Source | 3,174,584Source | 1,605,301Source |
| Operating Lease, Liability, NoncurrentUSD | 474,628Source | 505,053Source | 851,938Source | 313,298Source |
| Other Liabilities, NoncurrentUSD | 60,541,456Source | 56,294,108Source | 51,388,001Source | 46,930,936Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 4,278,027Source | 5,809,872Source | 5,170,809Source | 3,585,810Source |
| Long-term DebtUSD | 8,353,780Source | 8,480,533Source | 8,595,678Source | 8,730,402Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -2,429,385Source | 402,095Source | -9,521,669Source | 2,771,408Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 985,242Source | 693,847Source | 1,399,667Source | 1,498,883Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 417,101Source | 781,128Source | 816,639Source | 461,345Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 405,881Source | 1,999,759Source | 1,568,689Source | 1,720,386Source |
| Increase (Decrease) in InventoriesUSD | -56,190Source | -429,178Source | -360,445Source | -490,002Source |
| Increase (Decrease) in Accounts PayableUSD | 1,000,257Source | -423,720Source | 688,935Source | 115,527Source |
| Deferred Income Tax Expense (Benefit)USD | -2,819,000Source | -309,000Source | -6,751,000Source | -1,732,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 5,478,606Source | 6,010,910Source | 8,919,754Source | 8,572,647Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -975,332Source | -4,876,899Source | -8,144,754Source | -15,279,639Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 230,475Source | 2,403,708Source | 6,838,969Source | 12,168,459Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 169,502Source | 1,423,871Source | 799,036Source | 1,819,915Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -4,745,203Source | -979,118Source | -2,072,891Source | 147,862Source |
| Payments of Ordinary Dividends, Common StockUSD | 3,231,227Source | 2,020,539Source | 0Source | 7,672,728Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,029,012Source | 1,976,808Source | 1,808,751Source | 1,259,884Source |
| Income Taxes Paid, NetUSD | 4,594,638Source | 2,716,993Source | 1,820,802Source | 1,572,602Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 417,000Source | 781,000Source | 817,000Source | 461,000Source |
| Amortization of Debt Issuance CostsUSD | 20,822Source | 21,237Source | 21,631Source | 15,834Source |
| Amortization of Intangible AssetsUSD | 58,000Source | 68,000Source | 96,000Source | 96,000Source |
| DepreciationUSD | 927,000Source | 626,000Source | 326,000Source | 333,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 0Source | 105,887Source | 122,113Source | 446,200Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -48,304Source | — | 0Source | 407,344Source |
| GoodwillUSD | 1,941,411Source | 1,941,411Source | 1,941,411Source | 1,941,411Source |
| Income Tax Expense (Benefit)USD | 92,232Source | 2,402,026Source | -3,842,826Source | 547,540Source |
| InterestExpenseNonoperatingUSD | 2,066,256Source | 1,864,684Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | -806,267Source | 1,076,051Source | 50,777Source | -38,972Source |
| Net Income (Loss) Attributable to ParentUSD | -2,429,385Source | 402,095Source | -9,521,669Source | 2,771,408Source |
| Nonoperating Income (Expense)USD | -2,819,547Source | -676,163Source | -1,060,463Source | -705,519Source |
| Operating Lease, ExpenseUSD | 456,204Source | 442,874Source | 400,716Source | 346,098Source |
| Other Nonoperating Income (Expense)USD | 52,976Source | 6,583Source | 3,441Source | 1,676Source |
| Proceeds from Stock Options ExercisedUSD | 23,101Source | 76,402Source | 0Source | 551,274Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 31,566,321Source | 31,986,106Source | 31,343,695Source | 30,336,749Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 7,376,648Source | 7,947,752Source | 8,442,310Source | 8,792,358Source |
| Selling, General and Administrative ExpenseUSD | 18,220,708Source | 18,521,218Source | 17,115,514Source | 15,580,274Source |
| Operating Income (Loss)USD | 482,394Source | 3,480,284Source | -12,304,032Source | 4,024,467Source |
| Other Nonoperating Income (Expense)USD | 52,976Source | 6,583Source | 3,441Source | 1,676Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -2,337,153Source | 2,804,121Source | -13,364,495Source | 3,318,948Source |
| Income Tax Expense (Benefit)USD | 92,232Source | 2,402,026Source | -3,842,826Source | 547,540Source |
| Net Income (Loss) Attributable to ParentUSD | -2,429,385Source | 402,095Source | -9,521,669Source | 2,771,408Source |
| Earnings Per Share, BasicUSD per share | -0.3Source | 0.05Source | -1.14Source | 0.33Source |
| Earnings Per Share, DilutedUSD per share | -0.3Source | 0.05Source | -1.14Source | 0.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,068,777Source | 8,130,676Source | 8,340,839Source | 8,465,568Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,068,777Source | 8,212,510Source | 8,340,839Source | 8,483,994Source |
| Interest Expense (non-operating)USD | 2,066,256Source | 1,864,684Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 58,000Source | 68,000Source | 96,000Source | 96,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | 0.25Source | — | 0.9Source |
| Costs and ExpensesUSD | 31,083,927Source | 28,505,822Source | 43,647,727Source | 26,312,282Source |
| Current Income Tax Expense (Benefit)USD | 2,911,000Source | 2,711,000Source | 2,908,000Source | 2,280,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 751,474Source | 483,522Source | 1,124,228Source | 1,119,528Source |
| Interest ExpenseUSD | 2,066,256Source | 1,864,684Source | 1,236,794Source | 1,521,767Source |
| Nonoperating Income (Expense)USD | -2,819,547Source | -676,163Source | -1,060,463Source | -705,519Source |
| Operating Lease, ExpenseUSD | 456,204Source | 442,874Source | 400,716Source | 346,098Source |
| Research and Development ExpenseUSD | 376,263Source | 1,242,536Source | 1,171,456Source | 384,789Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 31,566,321Source | 31,986,106Source | 31,343,695Source | 30,336,749Source |
Filing attachments
ccel-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 ccel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL RECEIVES ACCEPTANCE OF COMPLIANCE PLAN FROM NYSE AMERICAN OLDSMAR, FL. - May 8, 2026 - Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American) has accepted the Company’s previously submitt…
Read attachment ↗ccel-ex99_1.htm · 8-K · 2026-03-12
EX-99.1 2 ccel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL RECEIVES NYSE AMERICAN CONTINUED LISTING NOTICE OLDSMAR, FL. - March 12, 2026 - Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”…
Read attachment ↗ccel-ex99_1.htm · 8-K · 2025-05-08
EX-99.1 2 ccel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND OLDSMAR, FL - May 8, 2025 - Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternat…
Read attachment ↗